GSK-BEL112233

Study Sponsor: GSK

Study Title

A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States

Medicine or Vaccine (generic name)

belimumab

Sponsor Identification Number

BEL112233

Trial Registry Identification Number(#'s)

NCT00724867

Medical Condition

Systemic Lupus Erythematosus

Phase

Phase 3

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=112233

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00724867

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to HGS1006-C1056. The data is available in CDISC format.

Date Added to this Site

January 2019